<unk>  (trade name NovoEight) is a recombinant antihemophilic factor VIII used for the treatment of and prophylaxis of bleeding patients with haemophilia A. It is marketed by Novo Nordisk. It was approved in the United States, the European Union, and Japan in 2013.
Turoctocog alfa
Vonicog alfa
Desmopressin
Efmoroctocog alfa
Drotrecogin alfa
Celadrin 
Oprelvekin
Triptorelin